Bangladesh was close to eliminating measles – now it has the world’s largest outbreak

Bangladesh was close to eliminating measles. Now the country is battling the world’s largest outbreak, with more than 166,000 suspected cases and nearly 1,000 r...

SmartCella secures key patents in the US and Japan

Swedish drug-delivery company SmartCella has secured the main patent for its Extroducer device in the US and Japan, completing global protection following the E...

Regulatory milestone strengthens Xinnate’s EB program

Xinnate has received a notification from the U.S. Food and Drug Administration (FDA) that may bring significant advantages in the development of the company’s t...

Nordic newcomer on an acquisition drive – snaps up four Swedish distributors

Over the past five years, Medu Group has built a Nordic distribution business. “We aim to become one of the major Nordic distributors in medtech,” says Magnus S...

Turning insights into impact

Explore the ZEISS INNOVATION SUMMIT 2026.

Novo Nordisk Pharmatech CEO to step down

Ulla Grove Krogsgaard Thomsen has decided to leave Novo Nordisk Pharmatech to pursue af different career.

Novartis hit by another major setback – shares plunge

Novartis has suffered another major pipeline setback. A key drug candidate acquired through its $12bn takeover of Avidity has failed in phase III, sending the c...

BII injects fresh millions into six ‘promising’ Danish startups

BioInnovation Institute (BII) is allocating new convertible loans of EUR 1.3 million to six Danish startups previously backed by the organisation.

Political consensus on how to bring more new medicines to Sweden

Sweden is losing ground when it comes to access to new medicines. Ahead of the election, the country’s parliamentary parties are unusually united on what needs ...

Novo Nordisk halts two more heart drug trials

Novo Nordisk is discontinuing two Phase III trials of its drug candidate ziltivekimab in heart failure and inflammation.

Four in ten children shed obesity in Novo trial

A phase III study testing semaglutide in children with obesity met its primary endpoint, Novo Nordisk reports.

IVDR - From Fundamentals to Technical Documentation – Get Ready for Certification

The EU IVDR Regulation has significantly changed the requirements for in vitro diagnostic (IVD) medical devices. IVDR (EU 2017/746) replaces the former IVDD Dir...

IVDR - From Fundamentals to Technical Documentation – Get Ready for Certification

On-demand webinar: ZEISS Lightfield 4D for high-content tumor microtissue screening

From reliable and scalable 3D models to quantitative insights.

“Not the results we hoped for” – Novartis’ heart study shows no benefit

Novartis’ drug candidate pelacarsen, aimed at a well‑known cardiovascular risk factor, failed to reduce the risk of heart attack, stroke and cardiovascular deat...

FDA Breakthrough Device Designation lifts Neola shares

Lund-based Neola Medical has been granted the FDA’s Breakthrough Device Designation for Neola, the company’s medical device for continuous lung monitoring in pr...

Astra Zeneca receives US approval for Etcamah

The pharmaceutical company Astra Zeneca has received accelerated FDA approval for Etcamah in combination with a CDK4/6 inhibitor for advanced HR-positive, HER2-...

Dialysis company hit with $15M bill after massive patient data breach

A cyberattack last year exposed the personal data of millions of patients at dialysis provider DaVita. Now the bill has arrived for the company: 15 million dollars in damages.

Sweden takes new steps to tackle oestrogen shortages

Sweden has struggled with shortages of oestrogen medicines for years, forcing women going through the menopause to switch products or search from pharmacy to ph...

Lithuania accelerates life science ambitions with major cell therapy investment

A new center for cell therapy and personalized medicines has opened in the Lithuanian capital, Vilnius.

BII and GU Ventures collaborate on oligonucleotide project

Denmark’s BioInnovation Institute (BII) and Sweden’s GU Ventures are collaborating through a new cross-border project focused on therapeutic oligonucleotides.

ZEISS elevates ophthalmic workflows at ESCRS with new surgical and digital advancements

ZEISS Medical Technology will showcase its latest portfolio advancements and workflow enhancements for cataract, corneal refractive, and retina, at the European...

AbbVie’s myeloma candidate hits both goals in Phase III

The pharmaceutical company Abbvie's etentamig met both primary endpoints in the Phase III CERVINO study in relapsed or refractory multiple myeloma.

SGS webinar on IVDR & MDR certification process